Back to top

Analyst Blog

The European Medicines Agency (EMA) recently accepted the Marketing Authorisation Application (MAA) filed by Actelion (ALIOF) seeking approval for its pulmonary arterial hypertension (PAH) candidate, macitentan.

We note that the marketing application was submitted on the basis of data from a long-term, pivotal, and event-driven phase III outcome study (SERAPHIN: n=742). The study evaluated macitentan at two doses (10 mg and 3mg) in patients suffering from PAH. Results from the phase III study revealed that treatment with macitentan (10mg once daily) reduced the risk of morbidity and mortality event by 45% compared to placebo. The risk was reduced by 30% in PAH patients treated with the 3 mg dosage of the drug.

Data from the study also revealed that the risk of death or hospitalization due to PAH was 50% and 33% lower for patients in the 10 mg and 3 mg arms, respectively, compared to placebo. Patients in the study were treated for a period of three and a half years and the candidate was well tolerated among these patients. Actelion further reported that the number of serious adverse events was lower in patients treated with macitentan than placebo.

We note that macitentan is also under review in the US for the PAH indication. In October 2012, Actelion submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval of macitentan for the indication. Actelion also intends to get macitentan approved for PAH in Switzerland and other major markets across the globe.

Our View

Actelion currently has three marketed products, Tracleer, Ventavis and Veletri, for the treatment of PAH. We remind investors that during the first nine months of 2012 the company reported a decline in sales in Tracleer and Ventavis from the year-ago period. Veletri, launched in 2010, however did very well during the period.

Actelion currently competes with players such as Gilead Sciences (GILD - Analyst Report) and United Therapeutics (UTHR - Analyst Report) in the PAH space. Actelion’s top line would be boosted further if macitentan is cleared in the US and the EU.

Switzerland-based Actelion carries a Zacks #1 Rank (Strong Buy) in the short run.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%